Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) was upgraded by stock analysts at Raymond James to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.
Eupraxia Pharmaceuticals Trading Down 3.4 %
Shares of EPRX opened at $2.85 on Wednesday. Eupraxia Pharmaceuticals has a one year low of $2.48 and a one year high of $6.78.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share for the quarter.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- What is a Short Call Butterfly Spread? Explanation with Examples
- What Are Dividend Challengers?
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- Insider Trading – What You Need to Know
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
